Get the Stockscreener App
14.01
1.08%
0.15
Pre-market:
14.11
0.10
+0.71%
Immunic Inc stock is traded at $14.01, with a volume of 138.92K.
It is up +1.08% in the last 24 hours and up +15.98% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
See More
Previous Close:
$13.86
Open:
$13.96
24h Volume:
138.92K
Relative Volume:
0.51
Market Cap:
$190.84M
Revenue:
-
Net Income/Loss:
$-104.29M
P/E Ratio:
-2.3223
EPS:
-6.0329
Net Cash Flow:
$-81.45M
1W Performance:
+16.17%
1M Performance:
+15.98%
6M Performance:
+128.29%
1Y Performance:
+74.06%
1-Day Range:
$13.51
$14.40
1-Week Range:
$11.55
$14.40
52-Week Range:
$5.062
$15.77
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
14.01 | 190.84M | 0 | -104.29M | -81.45M | -6.0329 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | Stifel | Buy |
| Apr-15-26 | Downgrade | D. Boral Capital | Buy → Hold |
| Mar-24-26 | Initiated | Guggenheim | Buy |
| Nov-07-25 | Initiated | Roth Capital | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
IMUX - Finviz
Immunic Inc Stock (US45256V1061): Biotech share in focus after recent volatility - AD HOC NEWS
Why Did IMUX Stock Surge 33% Pre-Market Today? - Stocktwits
Immunic to showcase IMU-856 research at June conferences - Proactive financial news
Immunic to Participate in Investor, Industry and Scientific Conferences in June - AD HOC NEWS
IMUX Q1 2026 Earnings: Wider-Than-Expected Loss Per Share Amid Pipeline ProgressEarnings Cycle Outlook - newsline.com
IMUX Stock Price, Quote & Chart - ChartMill
Immunic stock (US45256V1061): Pipeline updates keep investor focus on late-stage catalysts - AD HOC NEWS
Immunic Inc. (IMUX) Q1 2026 Earnings: Wider-than-Expected Loss Triggers Sharp SelloffEarnings Sentiment Score - newsline.com
Cost of goods sold of Immunic, Inc. – DUS:10V - TradingView
IMUX Q1 2026 Earnings: EPS Misses Estimates, Stock Dips 3.24%Final Results - newsline.com
IMMUNIC (IMUX) CEO Erik Lundgren files initial Form 3 insider report - Stock Titan
MS expert takes the helm - European Biotechnology Magazine
Immunic (IMUX) proxy details 6M-share plan increase and 22.2% dilution - Stock Titan
Stifel Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Immunic to Present Phase 2 CALLIPER Trial Data on Vidofludimus Calcium Impact on Neurofilament Light Chain in Progressive MS at CMSC 2026 - geneonline.com
Immunic Presents Promising Phase 2 CALLIPER Data for Vidofludimus Calcium in Progressive Multiple Sclerosis, Highlighting Safety, Efficacy, and Novel Disability Assessment Methods 1 - Minichart
Market movers: Dell, Immunic, Dollar Tree, Synopsys, Best Buy, Giyani Metals... - Proactive financial news
Immunic presents new vidofludimus calcium data at multiple sclerosis conference - Yahoo! Finance Canada
Immunic Appoints New CEO to Lead MS Strategy - The Globe and Mail
Immunic Presents Additional Phase 2 Calliper Trial Data for Vidofludimus Calcium At Cmsc Annual Meeting - marketscreener.com
Immunic to Present Additional Phase 2 CALLIPER Data Showing Favorable Safety and Disability Signals for Vidofludimus Calcium - TradingView
New CALLIPER MS data for vidofludimus calcium at CMSC 2026 (IMUX) - Stock Titan
Progressive MS drug shows similar safety to placebo, no mood worsening 120 weeks - Stock Titan
Immunic appoints Erik Lundgren as new CEO By Investing.com - Investing.com Australia
Immunic names Erik Lundgren as CEO; Daniel Vitt steps down - MSN
Immunic Therapeutics Welcomes New CEO Erik Lundgren - Contract Pharma
Small cap wrap: Standard Uranium, Blockmate Ventures, Abacus Global, Immunic, Virtuix… - Proactive financial news
Immunic (IMUX) Appoints Erik Lundgren as New CEO Effective May 2 - GuruFocus
Immunic stock holds at Buy as Stifel cites new CEO ahead of trial By Investing.com - Investing.com India
Immunic stock holds at Buy as Stifel cites new CEO ahead of trial - Investing.com Australia
Immunic, Inc. Announces Chief Executive Officer Changes - marketscreener.com
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials - Yahoo Finance
Immunic lures former Roche exec Erik Lundgren to be its CEO - The Pharma Letter
Immunic Names Erik Lundgren Chief Executive - Moomoo
Erik Lundgren becomes Immunic (Nasdaq: IMUX) CEO with milestone-tied pay - Stock Titan
Immunic appoints Erik Lundgren as new CEO - Investing.com UK
Press Release: Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer - Moomoo
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO - Yahoo Finance
William Blair Maintains Immunic(IMUX.US) With Buy Rating - Moomoo
Immunic (IMUX) Surges 6% as Biotech Shares Rebound – Key Levels to WatchInitial Balance - newsline.com
Wolfe Research initiated coverage on Immunic - Quantisnow
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):